FRCPath Haem Part 1 MCQ-Gen Haem 213
- amirhayat2527
- Oct 30
- 0 min read
A 68yr-old pt with cold agglutinin disease remains transfusion-dependent despite rituximab. She is started on sutimlimab. Its mechanism of action?
Anti CD123
C5 Inhibitor
C1 Inhibitor
Anti CD22
Correct Answer: C1 Inhibitor
Explanation:
Sutimlimab is a humanized monoclonal antibody that targets complement component C1s, a serine protease in the classical complement pathway.
Sutimlimab inhibits C1s in the classical complement pathway, preventing complement-mediated RBC destruction in cold agglutinin disease.